KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Capital Expenditures (2016 - 2025)

Inovio Pharmaceuticals' Capital Expenditures history spans 16 years, with the latest figure at $67951.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 86.07% year-over-year to $67951.0; the TTM value through Sep 2025 reached $158254.0, down 67.56%, while the annual FY2024 figure was $487832.0, 52.02% up from the prior year.
  • Capital Expenditures for Q3 2025 was $67951.0 at Inovio Pharmaceuticals, up from $30930.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $717212.0 in Q2 2022 and bottomed at -$695863.0 in Q4 2022.
  • The 5-year median for Capital Expenditures is $59373.0 (2025), against an average of $85332.0.
  • The largest annual shift saw Capital Expenditures crashed 692.5% in 2021 before it skyrocketed 440.19% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at -$382533.0 in 2021, then plummeted by 81.91% to -$695863.0 in 2022, then surged by 103.44% to $23915.0 in 2023, then skyrocketed by 1939.86% to $487832.0 in 2024, then crashed by 86.07% to $67951.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Capital Expenditures are $67951.0 (Q3 2025), $30930.0 (Q2 2025), and $59373.0 (Q1 2025).